Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

ZOLL and Reflectance Medical Form Development Agreement to Incorporate Mobile CareGuide Sensor into ZOLL Monitor/Defibrillators



  ZOLL and Reflectance Medical Form Development Agreement to Incorporate
  Mobile CareGuide Sensor into ZOLL Monitor/Defibrillators

     New Noninvasive Sensor Technology Detects Patients at Onset of Shock

Business Wire

CHELMSFORD, Mass. -- April 18, 2013

ZOLL Medical Corporation, a manufacturer of resuscitation devices and related
software solutions, announced today that it has entered into an agreement with
Reflectance Medical, Inc. of Westborough, Mass., to develop and market a 
ruggedized version of the Mobile CareGuide™  sensor for detecting the onset of
shock in patients during air and ground military, and EMS patient transports,
as well as hospitalizations.

Reflectance Medical’s CareGuide sensor continuously and noninvasively monitors
tissue metabolism and can be used to determine when a patient has undetected
internal bleeding and may be in danger of going into shock.

Rapid treatment of traumatic injuries and shock has been shown to help save
lives and reduce complications. By incorporating these new clinical
parameters, ZOLL’s patient monitor/defibrillators will provide more than just
standard vital signs monitoring. Having early indicators of blood volume loss
and impending circulatory failure in the ZOLL monitor/defibrillators will
ensure rapid treatment is given to the patients who need it the most.

The technology measures muscle oxygen saturation (SmO[2]), to determine the
adequacy of tissue perfusion. Mobile CareGuide can also measure muscle pH^1,
an indication of acidosis as well as blood hematocrit^1, another key parameter
to assess patient status.

The goal of resuscitation from shock is to reverse acidosis and restore
adequate blood flow and oxygen to all organs. Mobile CareGuide uses
near-infrared light and patented algorithms to noninvasively analyze and
report the blood chemistry of muscle tissue, which is the last organ to
recover from traumatic injury and shock.

“Combining Reflectance’s CareGuide technology with ZOLL’s Propaq® M, Propaq
MD, and X Series® platforms of vital signs monitors and monitor/defibrillators
provides clinicians the ability to triage casualties, especially those who
appear stable, but are actually in shock,” said Jonathan A. Rennert, President
of ZOLL. “This technology has promising applications for both military and EMS
services and we anticipate this becoming a standard in evaluating the status
of trauma patients.”

“Being able to draw upon ZOLL’s extensive knowledge and experience in the
military and EMS markets to develop a field-deployable CareGuide product for
use outside the hospital can make a big impact on improving patient care,”
said Babs Soller, President of Reflectance Medical. “We also anticipate
applying ZOLL’s expertise in resuscitation to expand the CareGuide technology
to additional patient populations including cardiac arrest patients.”

About Reflectance Medical

Reflectance Medical, Inc. is a privately held, commercial-stage company, which
emerged from the University of Massachusetts Medical School. Reflectance is
focused on the development of innovative, patent-protected physiologic sensors
to noninvasively and continuously assess patient metabolic status. The
company’s CareGuide technology provides data that helps clinicians identify
life-threatening events earlier than standard vital sign parameters. The
technology provides real-time information to guide the application of
treatment to avoid costly and harmful patient complications. For more
information, visit www.reflectancemedical.com.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets
medical devices and software solutions that help advance emergency care and
save lives, while increasing clinical and operational efficiencies. With
products for defibrillation and monitoring, circulation and CPR feedback, data
management, fluid resuscitation, and therapeutic temperature management, ZOLL
provides a comprehensive set of technologies that help clinicians, EMS and
fire professionals, and lay rescuers treat victims needing resuscitation and
critical care. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding
company Asahi Kasei Corp., with operations in the chemicals and fibers, homes
and construction materials, electronics, and health care business sectors. Its
health care operations include devices and systems for critical care,
dialysis, therapeutic apheresis, transfusion, and manufacture of
biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and
nutritional products. With more than 25,000 employees around the world, the
Asahi Kasei Group serves customers in more than 100 countries. For more
information, visit www.asahi-kasei.co.jp/asahi/en/.

Copyright © 2013 ZOLL Medical Corporation. All rights reserved. X Series and
ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in
the United States and/or other countries. Propaq is a registered trademark of
Welch Allyn, Inc. Mobile CareGuide is a trademark of Reflectance Medical, Inc.
Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All
trademarks are the property of their respective owners.

^1Mobile CareGuide parameters pH and hematocrit are not yet cleared by the FDA
for commercial sale to hospitals and other clinical settings.

Contact:

ZOLL Medical Corporation
Diane Egan, +1 978-421-9637
degan@zoll.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement